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Summary
Transcription activation domains (ADs) are inherently disordered proteins that often target 
multiple coactivator complexes, but the specificity of these interactions is not understood. Efficient 
transcription activation by yeast Gcn4 requires its tandem ADs and four activator-binding domains 
(ABDs) on its target, the Mediator subunit Med15. Multiple ABDs are a common feature of 
coactivator complexes. We find that the large Gcn4-Med15 complex is heterogeneous and contains 
nearly all possible AD-ABD interactions. Gcn4-Med15 forms via a dynamic fuzzy protein-protein 
interface, where ADs bind the ABDs in multiple orientations via hydrophobic regions that gain 
helicity. This combinatorial mechanism allows individual low-affinity and specificity interactions 
to generate a biologically functional, specific, and higher affinity complex despite lacking a 
defined protein-protein interface. This binding strategy is likely representative of many activators 
that target multiple coactivators, as it allows great flexibility in combinations of activators that can 
cooperate to regulate genes with variable coactivator requirements.
Graphical abstract
In Brief: Tuttle et al. report a “fuzzy free-for-all” interaction mechanism that explains how 
seemingly unrelated transcription activators converge on a limited number of coactivator targets. 
The mechanism provides a rationale for the observation that individually weak and low-specificity 
interactions can combine to produce biologically critical function without requiring highly ordered 
structure.
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INTRODUCTION
Transcription activators lie at the endpoint of signaling pathways that control transcription in 
response to development, cell growth, stress, and other physiological signals (Levine et al., 
2014; Spitz and Furlong, 2012). A central challenge in understanding gene regulation is to 
determine the mechanism and specificity of activators. Transcription activation domains 
(ADs) are intrinsically disordered, lack a stable structure in the absence of a binding partner, 
and do not share obvious primary sequence similarity (Dyson and Wright, 2005; Hahn and 
Young, 2011; Nguyen Ba et al., 2012; Tantos et al., 2012; Tompa et al., 2014). Most known 
activators work by targeting transcription co-activator complexes to stimulate both 
transcription preinitiation complex (PIC) assembly and chromatin modifications (Hahn and 
Young, 2011; Weake and Workman, 2010). For over thirty years, a central mystery 
surrounding transcriptional activators, once referred to as “acidic blobs and negative 
noodles” (Sigler, 1988), has been: how do activators specifically target unrelated 
coactivators?
The acidic transcription activator Gcn4 from S. cerevisiae has properties common to many 
eukaryotic activators. Gcn4 contains tandem intrinsically disordered ADs (tADs) that target 
coactivators, including Mediator, SAGA, Swi/Snf, and/or NuA4 to regulate a large number 
of genes in response to metabolic stress (Brown et al., 2001a; Brzovic et al., 2011; Drysdale 
et al., 1995; Fishburn et al., 2005; Herbig et al., 2010; Jackson et al., 1996; Jedidi et al., 
2010; Natarajan et al., 2001; Qiu et al., 2016; Swanson et al., 2003; Warfield et al., 2014; 
Yoon et al., 2003). A key Gcn4 target is Med15/Gal11, a component of the Mediator tail 
module (Brzovic et al., 2011; Herbig et al., 2010; Jedidi et al., 2010; Warfield et al., 2014). 
Within its N-terminal half, Med15 contains four structured domains: a KIX domain 
(Novatchkova and Eisenhaber, 2004; Yang et al., 2006) and activator-binding domains 
(ABDs) 1; 2; and 3 that are recognized by Gcn4 (Herbig et al., 2010; Jedidi et al., 2010; 
Figure 1A). Although interactions have been detected between single-AD sequences and 
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individual ABDs, no single AD-ABD interaction is sufficient for efficient stimulation of 
transcription; high levels of activation are achieved only with the complete Med15 activator-
binding region and the tandem Gcn4 ADs (Herbig et al., 2010; Jedidi et al., 2010). This 
implies that a single AD-ABD interaction lacks sufficient affinity and/or specificity to 
promote transcription.
The use of multiple ADs and ABDs is not unique to Gcn4 and Med15. Other strong 
activators, such as VP16 and p53, contain tandem ADs, and coactivators, such as CBP, Swi/
Snf, and SAGA/NuA4, all contain multiple ABDs (Brown et al., 2001b; Chang et al., 1995; 
Díaz-Santín et al., 2017; Ferreon et al., 2009; Langlois et al., 2008; Prochasson et al., 2005; 
Regier et al., 1993; Unger et al., 1992; Walker et al., 1993). For example, multiple Gcn4 
binding sites have been implicated in the SAGA/NuA4 activator-binding subunit Tra1, and 
inactivation of any one site leads to reduced factor recruitment at Gcn4-dependent genes 
(Díaz-Santín et al., 2017; Knutson and Hahn, 2011). Likewise, optimum activator-Swi/Snf 
binding and Swi/Snf recruitment requires both ABDs within the Swi5 and Swi1 subunits of 
Swi/Snf (Ferreira et al., 2009; Prochasson et al., 2003). Whereas multiple ADs and ABDs 
appears to be a common theme in transcriptional regulation, the mechanism of how a 
multiplicity of AD-ABD interactions give rise to the affinity and specificity required for AD 
function remains undefined.
We previously showed that the Gcn4 central AD (cAD) binds to ABD1 with a fuzzy protein-
protein interface. Disordered on its own, cAD binds in multiple orientations to a shallow 
groove on ABD1, mediated almost entirely by hydrophobic interactions (Brzovic et al., 
2011). Because a single AD-ABD interaction is not sufficient for transcription activation 
(Herbig et al., 2010), an important question arising from our findings is whether a fuzzy 
binding mode is retained in the larger physiological Gcn4-Med15 complex with its full 
complement of ADs and ABDs. An alternative model predicts that multiple ADs and ABDs 
will lock into a specific, more stable complex with higher affinity binding and conventional 
protein-protein interfaces. Indeed, in two systems involving intrinsically disordered proteins 
(IDPs) and structured binding partners that have been characterized at a structural level, the 
IDPs form heterogeneous complexes with individual interacting partners but form stable 
distinct higher ordered structures when all binding partners are present (Dyson and Wright, 
2016; Saio et al., 2014). Such examples illustrate the importance of examining large natural 
complexes of IDPs and their targets. The distinction between the two possible mechanisms 
has important implications for which AD sequences can function together and the specificity 
of AD targets. A fuzzy binding mechanism is predicted to allow greater flexibility in AD-
AD and AD-ABD combinations compared to systems that lock into a specific complex.
To determine whether the Gcn4-Med15 complex forms a large complex with specific 
contacts or interacts via a large fuzzy interface, we characterized the interactions between 
the Gcn4 tADs and the four ABDs of Med15, both individually and as part of the larger 
Gcn4-Med15 complex. Our data demonstrate that the presence of multiple binding 
components leads to a large gain in the affinity of Gcn4-Med15 binding but does not lead to 
formation of a distinct ordered structure. The functional complex is a dynamic fuzzy “free-
for-all” involving hydrophobic patches of the tADs with ABD 1–3 and the KIX domain. Our 
results provide a general model for the mechanism of many activators that functionally bind 
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coactivators with multiple ABDs and demonstrate how multiple weak fuzzy interactions 
synergize to generate a biologically functional and specific interaction without adopting a 
unique protein-protein interface.
RESULTS
Both Gcn4 ADs Interact with All Individual Med15 ABDs
As a first step in characterization of the complete Gcn4-Med15 complex, we examined 
regions required for AD function and investigated the affinity of the individual and higher 
order AD-ABD interactions. The two Gcn4 ADs are the N-terminal (nAD; residues 1–100) 
and central (cAD; residues 101–134; Drysdale et al., 1995; Figure 1A). cAD is one of the 
shortest ADs known, with most of its function contained in a five-residue sequence motif 
WxxLF (residues 120–124; Warfield et al., 2014). In contrast, nAD function is dependent on 
clusters of hydrophobic residues located throughout residues 1–100 (Jackson et al., 1996). 
As AD function is usually confined to much shorter sequences, we examined whether any of 
the individual hydrophobic regions within nAD have function and whether any non-
hydrophobic regions of nAD contribute to activity. A series of deletions and alanine 
substitutions was made within a Gcn4 derivative lacking the cAD, and function was 
measured at ARG3 and HIS4, two Gcn4-dependent yeast genes (Figure S1). Consistent with 
prior results (Jackson et al., 1996), we found that Gcn4 nAD function requires four short 
hydrophobic regions (residues 4–16, 40–49, 65–69, and 94–98). We also found that residues 
between the clusters can be deleted with little or no detrimental effect. In several cases, 
deletions increase activity: deletion of residues between the first three hydrophobic regions 
to create one long hydrophobic region generates an AD with up to 4.6-fold higher activity 
relative to wild-type. Importantly, no individual short hydrophobic region has substantial 
activity when fused to the Gcn4 DNA-binding domain. Therefore, nAD function arises from 
multiple short non-redundant hydrophobic clusters with little or no inherent activity that 
together generate AD function.
We used isothermal calorimetry (ITC) and/or fluorescence polarization (FP) to measure the 
binding affinity of each AD and individual ABD and of a tAD-ABD1,2,3 complex (Table 1). 
With one exception, the individual pairwise interactions between individual nAD and cAD 
peptides and individual Med15 ABDs have similar low/modest affinities (Kd values of ~3–
20 μM). The exception is cAD binding to ABD2, which is ~10-fold weaker (150 μM Kd). 
Although the Med15 KIX domainis as important functionally for Gcn4 activation as any 
other ABD (Herbig et al., 2010), neither nAD nor cAD showed detectable KIX binding in 
our assays. The tandem AD polypeptide (Gcn4 residues 1–134) binds to each individual 
ABD with an affinity close to the stronger of the individual nAD or cAD interactions, 
suggesting that the individual Gcn4 ADs bind to the same or overlapping sites on the ABDs. 
A striking gain in affinity is observed when tAD binds to longer Med15 polypeptides 
containing multiple ABDs (ABD123 and KIX123). For example, tAD binding to ABD123 
(ABD1, ABD2, and ABD3 connected by short linkers) is about 20-fold higher affinity than 
the strongest piecemeal interaction, signifying that, when all domains are present, more than 
one ABD simultaneously contributes to binding. Notably, the presence of KIX along with 
ABD1,2,3 (KIX123) increases Gcn4 affinity by ~30%. Altogether, the results show that 
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multiple weak AD-ABD and KIX interactions in the full-length proteins combine to yield a 
much higher affinity Gcn4-Med15 interaction—in agreement with in vivo activation 
function.
A Heterogeneous Gcn4-Med15 Complex
A prediction of the fuzzy complex model for Gcn4-Med15 is that a complex containing 
multiple ADs and ABDs will not contain fixed protein-protein interactions and that 
individual ADs will sample multiple ABDs in different orientations, as was observed for 
cAD-ABD1 (Brzovic et al., 2011). The alternative “locked down” model predicts that 
specific protein-protein interactions will be adopted in the larger complexes. To test the two 
models, we used chemical crosslinking analyzed by mass spectrometry to detect interactions 
between the Gcn4 tAD and Med15 ABD123 or KIX123 (Figures 1B and 1C). Complexes of 
Gcn4 residues 1–140 (tAD) with either of the two Med15 constructs were treated with the 
zero-length crosslinker 1-ethyl-3-(3-dimethyla-minopropyl)carbodiimide hydrochloride 
(EDC) that links amine groups, such as those found in lysine side chains, to carboxylate 
groups, such as those found in the side chains of acidic amino acids. Identified crosslinks are 
summarized in Figures 1B and 1C and reported in Tables S1 and S2.
Crosslinks were observed between both ADs of Gcn4 and all four defined structural regions 
of Med15 (KIX domain and ABD1, 2, and 3) with one exception: no crosslinks between 
Gcn4 cAD and Med15 ABD3 were detected. In addition, fewer crosslinks were identified 
between the Gcn4 nAD and ABD3 than those involving the other subdomains, despite a 
similar number of potential crosslinking sites and the stronger intrinsic affinity of ABD3 
compared to ABD2 (Table 1). The KIX domain, with little or no detectable binding to Gcn4 
on its own, crosslinks extensively to Gcn4 in the large complex, mainly to nAD. Notably, the 
crosslink patterns between ABD1–3 and tAD are unchanged when the KIX domain is also 
present (KIX123 compared to ABD123). Thus, the crosslinking data show that KIX interacts 
directly with Gcn4, consistent with functional assays showing that KIX is as important as 
the individual ABD1, 2, and 3 domains for Gcn4 activation (Herbig et al., 2010). The results 
reveal that interactions involving the weaker binding domains of Med15 occur even when all 
domains are present, i.e., no domain outcompetes the others for AD binding. Such a 
mechanism predicts transient binding for each AD-ABD/KIX interaction.
tAD-Med15 Interactions Are a Sum of the Individual nAD and cAD Interactions
Together, the crosslinking and binding assays indicate that, whereas the large Gcn4-Med15 
complex has high affinity, it is nevertheless heterogeneous. Two models are consistent with 
this behavior: (1) each AD binds each ABD/KIX with a dynamic and fuzzy protein-protein 
interface or (2) AD-ABD binding is dynamic, but individual AD-ABD binding occurs with 
unique non-fuzzy interfaces. To distinguish between these models, we investigated the 
properties of the individual AD-ABD complexes by nuclear magnetic resonance (NMR) and 
compared the results to those of the complete complex.
We first examined the environment of the polypeptide backbones of nAD, cAD, and tAD 
upon Med15 binding. Titrations were carried out for each combination of 13C,15N-labeled 
nAD, cAD, and tAD binding to unlabeled ABD1, ABD2, ABD3, and ABD123. In these 
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experiments, effects on the isotopically labeled component due to binding the non-labeled 
(silent) component are observed in (1H,15N)- and (1H,13C)-heteronuclear single quantum 
coherence (HSQC) spectra. Titrations were taken to full saturation where possible, based on 
measured Kd values (Table 1).
In each titration series, NMR peaks for affected residues changed their resonance position 
continuously as a function of added binding partner until saturation was reached (e.g., 
Figure S2). The chemical shift perturbation (CSP) of a peak was calculated as the difference 
in its chemical shift in the spectrum of free AD and in the most saturated spectrum. CSPs 
can reflect a change in local environment as from a gain in secondary structure and/or from 
the change in electronic environment due to the proximity of a binding partner or through 
allosteric effects and are generally a strong proxy for assessing binding interactions. CSPs 
for AD backbone amide (NH) groups are displayed as histograms in Figure 2, with a panel 
for each individual ABD (Figures 2A–2C) and a panel for the combined ABD123 (Figures 
2D and S3A). Previously reported results for 15N-cAD:ABD1 are included here for a 
complete comparison (Brzovic et al., 2011). Several general features emerge from the large 
body of data. First, perturbations occur in hydrophobic residue clusters along the AD 
sequence that correspond to the previously identified hydrophobic regions in Gcn4. Second, 
the same clusters are perturbed regardless of which ABD has been added. Third, in all cases, 
the fourth nAD hydrophobic cluster (residues 94–98) shows the largest CSPs, followed by 
the cAD cluster (residues 120–124), with smaller shifts in each of the other hydrophobic 
regions. Fourth, there are no new perturbations associated with tAD binding to Med15; both 
the identity and magnitudes of the CSPs observed in the isolated nAD and cAD are retained 
in full-length tAD (Figures 2, S3A, and S3B). Thus, we find no additional cryptic interaction 
sites in the full-length Gcn4 tandem AD.
Whereas the same regions of the ADs show CSPs when binding to all ABDs, the magnitudes 
of the shifts depend on the ABD binding partner. The contribution of each cluster is parsed 
out in Figure S3B, in which the maximum CSPs in each cluster are compared. Two clusters 
dominate the binding to all ABDs: one in the nAD and cAD. The other nAD clusters 
contribute differently depending on the ABD: the larger CSPs for the weaker hydrophobic 
regions in the ABD2 and ABD3 titrations suggest that these clusters play a larger role in 
ABD2 and ABD3 binding than in ABD1. The CSPs of the weakly interacting hydrophobic 
regions of nAD do not increase in the full-length complex, as might occur if a sequential 
binding mechanism were in play. Instead, the CSPs in tAD:ABD123 resemble the 
component tAD:ABD complexes, indicating that the importance of the weaker hydrophobic 
clusters for activator function is not a result of new or stabilized interactions in the full-
length AD-ABD complex.
To further define the dynamic interface of Gcn4, we measured 15N-relaxation parameters for 
nAD and nAD:ABD1. An increase in the transverse relaxation rate, R2 (= 1/T2), upon 
binding is indicative of a role in binding for the affected residues (Delaforge et al., 2018). 
Upon binding ABD1, each of the hydrophobic regions of nAD shows an increase in R2, 
supporting the direct involvement of these regions in binding ABD1 (Figures 2E and S3C). 
Notably, even region 65–69, which exhibits only very small CSPs, has elevated R2 values 
upon binding ABD1. Consistent with the CSPs, the region of nAD including residues 94–98 
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shows the largest increase in R2. Residues ~20–38 show no change in R2 upon binding 
ABD1, which is consistent with transcription activity data that show residues in this region 
do not positively contribute to activity.
Gcn4 ADs Become Helical upon Binding Med15 ABDs
The primary interacting regions of many ADs become helical upon binding to their targets; 
e.g., residues 117–125 in Gcn4 cAD adopt helical structure upon ABD1 binding (Brzovic et 
al., 2011). We used the chemical shifts of free and bound nAD and cAD to assess secondary 
structure upon binding to Med15 ABDs (Tamiola and Mulder, 2012). Unbound nAD and 
cAD are completely disordered on their own, but each gains substantial helical content upon 
binding ABD1 (Figure S3D). The two most C-terminal hydrophobic clusters gain the most 
helicity: the nAD cluster exhibits up to 50% helical content, and the cAD cluster exhibits 
about 30%, whereas each of the other three nAD hydrophobic clusters show some helical 
character (<20%) upon binding ABD1. These analyses were performed on the two 
individual ADs where the most complete resonance assignments are available. However, 
chemical shifts in the tAD essentially match the component shifts of nAD and cAD (Figure 
2), allowing us to conclude that the same pattern and magnitude of helical structure is gained 
when tAD binds to ABD1.
Secondary structure gained by nAD upon binding to ABD2 qualitatively resembles that of 
nAD:ABD1, except that the C-terminal hydrophobic cluster shows only ~25% helical 
content (Figure S3D). This analysis was performed for spectra collected under saturating 
concentrations of each ABD, so the differences in estimated helicity of residues 94–98 
suggest either that the cluster spends less time bound to ABD2 than it does to ABD1 (i.e., 
has a faster off rate) and/or that it binds to ABD2 in non-helical as well as helical 
conformations. Overall, our analysis shows that (1) hydrophobic regions of ADs that interact 
with ABDs gain helical content upon binding and (2) the most frequent AD-ABD contacts 
are with Gcn4 hydrophobic clusters 94–98 and 120–124. Nevertheless, the other nAD 
hydrophobic clusters play an essential functional role (Figure S1) and contribute 
significantly to the overall interaction with Med15.
Structure of Med15 ABD2
Unlike the ADs, which are intrinsically disordered in their free states, ABDs typically adopt 
defined three-dimensional structures, though few ABD structures have been experimentally 
determined. We set out to determine structures for Med15 ABD2 (residues 277–368) and 
ABD3 (residues 484–651). Whereas NMR analysis showed that ABD3 is largely structured 
in the absence of AD binding (not shown), this domain has neither the solubility nor stability 
properties required for a full structure determination by NMR. In contrast, ABD2 was 
tractable for structure determination in its free state. Backbone and side-chain resonance 
assignments for 13C,15N-ABD2 were determined with overall completeness of 72% (Table 
S3). The chemical shifts predict that ABD2 contains three α helices (Figures 3 and S4B). A 
solution structure calculated using chemical shifts, nuclear overhauser effects (NOEs), and 
N-H residual dipolar couplings (RDCs) as experimental constraints is well defined, with a 
backbone root-mean-square deviation (RMSD) of 0.7 Å for the ordered regions (amino acids 
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[aas] 293–322 and 328–354) in the top 20 of 200 total generated structures (Figure 3A; PDB 
6ALY).
ABD2 is composed of three α helices: α1 (aas 292–299); α2 (aas 303–323); and α3 (aas 
330–354) with disordered N- and C-terminal tails (Figures 3A and S4B). Unlike ABD1 that 
binds cAD via a shallow hydrophobic groove (Brzovic et al., 2011), ABD2 has no obvious 
groove but instead has two hydrophobic surface patches (Figure 3B). One hydrophobic patch 
is created at the interface of α2 and α3 and is defined by the near stacking of three aromatic 
residues (F319, F330, and Y340). A second elongated patch includes α1 and spirals around 
the ABD2 structure. The ABD2 construct contains 18 charged residues, with a net positive 
charge of +4. A patch of positive charge separates the two hydrophobic patches (shown as 
blue; Figure 3C). The structure reveals that although ABD1 and ABD2 are both primarily 
composed of helices, helical ABDs do not conform to a single structural motif.
ABD1 and ABD2 Use Similar Strategies to Bind ADs of Different Sequence
To identify the AD-binding site(s) on the ABDs, we performed NMR titration experiments 
for each combination of 13C,15N-labeled ABD1 and ABD2 with unlabeled nAD, cAD, and 
tAD. We showed previously that cAD binds to ABD1 in a shallow hydrophobic groove as a 
fuzzy cAD-ABD1 complex (Brzovic et al., 2011). Remarkably, the CSPs in ABD1 are 
nearly identical, regardless of the AD binding partner (Figures 4A, 4C, and S4C). The 
similar CSP patterns induced upon binding to each of the three AD variants indicate that 
their interaction interface is essentially the same. Consistent with this, in a competition 
binding experiment in which unlabeled cAD was added to 15N-tAD + ABD1, all 15N-tAD 
peaks returned toward their chemical shifts in the unbound tAD spectrum, indicating that 
cAD can compete off both cAD and nAD residues (Figure S3E). The simplest explanation 
for these combined observations is that ABD1 does not bind the different ADs with a 
sequence-specific interface but rather as a “cloud” of hydrophobic character. This model is 
completely consistent with our earlier characterization of the fuzzy cAD-ABD1 complex.
ABD2 has substantially weaker affinity for cAD than for either nAD or tAD, suggesting that 
there may be different modes of ABD2 binding. Nevertheless, we again observe highly 
similar CSPs within ABD2 upon binding the nAD, cAD, and tAD peptides (Figures 4B, 4D, 
and S4D). The CSPs are widespread, with the largest perturbations occurring in/near the two 
ABD2 hydrophobic patches, regardless of whether nAD, cAD, or tAD is binding. Therefore, 
ABD1 and ABD2 each accommodate their AD binding partner(s) in a manner that is 
independent of the specific sequence of the AD, consistent with a fuzzy binding interface. 
However, ABD1 contains a single predominant binding groove, whereas two hydrophobic 
binding surfaces on ABD2 yield a less localized interaction that may explain the lower 
affinity for AD-ABD2 binding.
ABD1 and ABD2 Bind ADs with a Fuzzy Interface
In our previous studies, the definitive evidence for fuzzy binding of cAD-ABD1 derived 
from NMR spin-label experiments through measurement of paramagnetic relaxation 
enhancement (PRE) (Brzovic et al., 2011; Warfield et al., 2014). These studies showed that 
the cAD peptide bound ABD1 in multiple orientations. We performed analogous 
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experiments using a series of nAD, cAD, and tAD constructs, to which a single 
paramagnetic spin-label probe (4-(2-iodoacetamido)-TEMPO) was attached at sites near, but 
not in, a primary interacting region. Gcn4 residues T82, T105, and S117 were individually 
mutated to Cys to allow chemical attachment of the spin-label probe (Figure 5A). Groups 
that are close to a paramagnetic probe will suffer loss of peak intensity, quantified as Ipara/
Idia, where Idia (diamagnetic) is the reference intensity after reduction of the paramagnetic 
probe with ascorbic acid (see Figure S5 for 13C-HSQC spectra). If there is a preferred 
orientation of an AD in the AD-ABD complex, we expect different patterns of intensity loss 
when the spin label is on opposite ends of the AD peptide. We collected (1H,15N)- and (1H,
13C)-HSQC spectra for ABD1 and ABD2 with each of the spin-labeled ADs at ~50% 
saturation and plotted the location of intensity loss for NH and CH groups on the structures 
of ABD1 and ABD2 (Figures 5C and 5D, respectively). In every case, the observed patterns 
of intensity loss are highly similar, regardless of which TEMPO-AD was added (Figures 5B, 
S5B, and S6). The results indicate that the AD hydrophobic clusters bind without any 
discernable orientation bias, either when presented as individual ADs or when both nAD and 
cAD are present in the tandem construct. Altogether, the results fit a model in which fuzzy 
binding interfaces are used by each ABD-AD interaction. Because our results above showed 
that the interactions of tAD with ABD1 and ABD2 are equivalent in the individual and 
larger complex, we conclude that the AD-ABD interactions in the larger complex are also 
fuzzy. Using this mechanism for binding allows the multiple hydrophobic clusters in tAD to 
increase binding affinity through avidity but neither limits nor alters the possible ensemble 
of complexes that simultaneously exist.
DISCUSSION
A long-standing challenge in gene regulation has been to understand how seemingly 
unrelated transcription activators converge on a limited number of coactivator targets. This 
situation also raises the question of specificity in activator-coactivator interactions. For 
example, the fuzzy binding interface of the Gcn4 cAD with Med15 ABD1 has apparently 
low specificity and affinity and is not sufficient to efficiently activate transcription by itself 
(Brzovic et al., 2011; Herbig et al., 2010). Additionally, transcription of many genes requires 
multiple activators, and it is not clear how or why specific combinations of activators 
synergize. To investigate this long-standing question, we examined the binding of Gcn4 with 
the Mediator subunit Med15. Gcn4 has the common arrangement of tandem ADs whereas 
Med15 has multiple ABDs, typical of most coactivator complexes. Based on earlier findings, 
two models can explain the requirement for multiple ADs and ABDs in this system: (1) 
expansion of the cAD-ABD1 fuzzy binding mechanism to encompass dynamic fuzzy 
interfaces between the two ADs and all ABDs or (2) a mechanism where the final complex 
adopts a discrete state due to stable binding and specific AD-ABD interactions. The latter 
model has been observed in two systems involving IDP binding to structured proteins that 
contain multiple binding sites (Dyson and Wright, 2016; Saio et al., 2014), whereas the 
former model has yet to be observed experimentally. The distinctions between these models 
have important implications for the flexibility of AD-ABD combinations used in activation 
of specific genes and in regulatory circuits where activators can combine to give complex 
patterns of gene regulation. For example, the locked down mechanism requires pairing ADs 
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and ABDs in specific combinations, as only particular pairings are expected to work 
together. At the other extreme, activators like Gcn4, Gal4, VP16, and p53 interact with many 
unrelated coactivators. Use of one or the other mechanisms demands a tradeoff between 
specificity of interactions and flexibility in regulation of a wide variety of genes with 
different coactivator requirements.
Our results demonstrate unambiguously that Gcn4-Med15 binding uses a fuzzy free-for-all 
mechanism, where each AD interacts with all ABDs. NMR CSP and backbone dynamics 
data show that the primary interacting regions of tAD are residues 94–98 and 120–124, but 
that the other hydrophobic regions are also directly involved in binding to Med15 ABDs, as 
supported by transcription activity assays. Protein crosslinking results show that Gcn4-
Med15 is a heterogeneous complex, and binding measurements show that each Gcn4 AD 
can bind individual ABD1, 2, and 3 domains with micromolar affinity. Importantly, 
crosslinking experiments showed that multiple AD-ABD and AD-KIX binding interactions 
occur in the complex of full-length Gcn4 and Med15. Binding to KIX in the large complex 
is especially remarkable, as Gcn4-KIX binding is undetectable when separated from the rest 
of Med15. Surprisingly, crosslinks between Gcn4 and ABD3 are less frequent than with 
other ABDs, despite ABD3 having relatively high intrinsic affinity for both the nAD and 
cAD. Whereas it is possible that ABD3 does not efficiently bind Gcn4 in the large Gcn4-
Med15 complex, we think it likely that binding occurs but that fewer crosslinks are detected 
for technical reasons. Crosslinking efficiency and/or detection of crosslinked products can be 
affected if crosslinkable residues are not in close proximity or if crosslinked peptides are not 
well detected by mass spectrometry (MS). The fact that ABD3 is as functionally important 
for Gcn4 activation as KIX, ABD1, and ABD2 (Herbig et al., 2010), combined with 
relatively strong Gcn4-ABD3 binding (Table 1), makes a strong case that this interaction 
does occur in the context of the larger complex. Also consistent with the fuzzy binding 
mechanism, our NMR results show that both ADs of Gcn4 bind Med15 independently 
within the large Gcn4-Med15 complex. Importantly, ABD1 and ABD2 have highly similar 
NMR CSPs, regardless of which AD variant is binding. Such behavior is not consistent with 
a specific binding interface and is again in agreement with the fuzzy binding model where 
the ABDs seem to recognize a cloud of hydrophobicity rather than a specific sequence. 
Finally, multiple spin-label probes positioned on the tAD showed unequivocally that tAD 
binds in multiple orientations on both ABD1 and ABD2.
Med15 is a subunit of the Mediator tail module (Med2, 3, 5, 15, and 16), and whether 
activator-Med15 binding has a role in the architecture and function of the tail is not yet clear. 
There is contradictory information on the function and relationship of these subunits in tail 
module function. In some reports, the function of several tail subunits seems redundant, 
whereas, in others, these subunits make equal and important contributions to transcription 
activation (Ansari et al., 2012; Ansari and Morse, 2012; Zhang et al., 2004). It is possible 
that Gcn4-Med15 binding causes a conformational change in tail or leads to other changes in 
the Mediator head or middle modules that affect function. However, in recent cryoelectron 
microscopy (cryo-EM) structures of yeast Mediator with and without other PIC components, 
the Med15-containing tail module remains disordered even when Gcn4 is present (Nozawa 
et al., 2017; Robinson et al., 2015; Tsai et al., 2017). This is consistent with our findings that 
Med15 contains multiple well-ordered activator binding domains separated by long flexible 
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linkers and that interactions of Gcn4 with each ABD do not result in a well-ordered 
complex. In agreement with these results, crosslinking of the Gcn4 ADs within the PIC is 
almost exclusive to Med15, whereas Med2, 3, 5, and 16 form a network of interactions that 
primarily crosslink with the Med15 C-terminal half that lies outside of the activator-binding 
region (Robinson et al., 2016). A crosslink between Gcn4 and Med16 was observed at a low 
frequency, but it is not known whether these polypeptides interact directly.
Whereas activator-Med15 binding naturally occurs in the larger context of the complete 
Mediator complex, it seems likely that the fuzzy interfaces described here will exist in this 
larger complex. The simple nature of the binding interfaces on ABD1 and ABD2 and the 
variety of AD sequences that bind seem to preclude precise molecular complementarity. 
Given the sequence variability of the ADs studied here and our previous findings that even 
more strongly binding synthetic ADs bind with a fuzzy interface (Warfield et al., 2014), we 
expect that fuzzy binding is a general feature of many large AD-Med15 complexes. 
Furthermore, the Med15 ABDs may be representative of protein domains designed to 
accommodate fuzzy interactions.
Whereas both ABD1 and ABD2 bind Gcn4 with a fuzzy interface, each uses a different type 
of surface feature to bind ADs. ABD1 has a shallow hydrophobic groove that can 
accommodate a variety of hydrophobic sequences in different orientations (Brzovic et al., 
2011; Warfield et al., 2014), whereas ABD2 uses two separate hydrophobic surface patches. 
It is hard to imagine that individual AD-ABD interactions are specific enough for a 
biological response. However, the combination of ADs and multiple ABDs within Mediator 
gives rise to binding specificity, higher affinity, and function and allows important 
contributions to be made by very weak protein-protein interactions (e.g., Gcn4-KIX and 
cAD-ABD2; Figure 6). This combinatorial mechanism likely explains why most coactivator 
complexes examined to date (e.g., Mediator, Swi/Snf, and NuA4/SAGA) have multiple 
ABDs. Even though not every activator has multiple ADs, many ADs bind DNA as dimers, 
and a common regulatory strategy is to require combinations of transcription factors to bind 
to regulatory regions for efficient activation of transcription. We imagine that this 
mechanism has the same effect as multiple ADs in a single factor. It has been proposed that 
the fuzzy binding mechanism leads to higher affinity binding, in part by decreasing the 
dissociation rate due to multiple independent binding sites on both binding partners (Olsen 
et al., 2017).
In the broader context, it is important to note that not all activators work by this mechanism. 
There are several instances of ADs that bind their targets using specific protein-protein 
interfaces with much higher affinity. An intermediate case is that of ETV4 and Med25. On 
its own, the ETV4 DNA-binding domain (DBD) binds multiple sites on Med25, including 
the primary ETV4 AD binding site. When both ETV4 AD and DBD are present, a tighter 
binding complex is formed in which the AD binds one site, whereas the DBD may retain a 
fuzzy interface involving two other Med25 binding surfaces (Currie et al., 2017). 
Alternatively, the mammalian coactivator CBP contains numerous activator-binding domains 
whose individual ABDs partner with specific transcription activators using high-affinity 
conventional protein-protein interfaces (Dames et al., 2002; Demarest et al., 2002; Freedman 
et al., 2002; Radhakrishnan et al., 1997; Waters et al., 2006; Zor et al., 2004). We believe 
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that the fuzzy binding mode identified for Gcn4-Med15 is another common regulatory 
strategy and can account for the behavior in instances where ADs are known to interact with 
multiple unrelated coactivators. This strategy can generate great flexibility in developing 
new regulatory circuits where many combinations of activators can regulate a wide variety 
of genes with different coactivator requirements. It seems likely that a similar strategy will 
be utilized in other biological systems that utilize IDPs reacting with multiple partners.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in Supplemental 
Experimental Procedures.
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the corresponding authors, Steve Hahn (shahn@fredhutch.org) or Rachel Klevit 
(klevit@u.washington.edu).
Yeast Strains and Plasmids
Yeast strain SHY823 (Δgcn4, leu2) was transformed with the following LEU2 and GCN4-
derivative plasmids for protein expression and mRNA analysis: pRS315 (vector—no 
GCN4), pSH940 (WT GCN4), and pSH943 (Gcn4 Δ101–124; [nAD] with the flexible 
linker: GSGSGS at the junction of the internal deletion) (Herbig et al., 2010). Gcn4 nAD 
mutations were generated in pSH943 by site-directed mutagenesis. All Gcn4 derivatives 
contained a C-terminal 3X-FLAG tag.
mRNA Analysis
RNA was extracted and assayed in triplicate by qRT-PCR, and the results were analyzed as 
described (Herbig et al., 2010).
Protein Purification
All proteins were expressed in BL21 (DE3) RIL E. coli. Med15 484–651 (ABD3), Med15 
158–651 Δ239–272, Δ373–483 (ABD123), and Med15 1–651 Δ239–272, Δ373–483 
(KIX123) were expressed as N-terminal His6-tagged proteins. All other Med15 and Gcn4 
constructs were expressed as N-terminal His6-SUMO-tagged proteins. Cells were lysed in 
50 mM HEPES (pH 7.0), 500 mM NaCl, 40 mM imidazole, 10% glycerol, 1 mM PMSF, 5 
mM DTT and purified using Ni-Sepharose High Performance resin (GE Healthcare). 
Proteins were eluted in 50 mM HEPES (pH 7.0), 500 mM NaCl, 500 mM imidazole, 10% 
glycerol, 1 mM PMSF, 1 mM DTT. Purified SUMO-tagged proteins were concentrated 
using 10K MW cutoff centrifugal filters (Millipore), diluted 10× in 50 mM HEPES (pH 7.0), 
500 mM NaCl, 40 mM imidazole, 10% glycerol, 1 mM PMSF, 5 mM DTT, and digested 
with SUMO protease for 3–5 hr at room temperature using ~1:800 protease: protein ratio. 
Cleaved His6-Sumo tag was removed using Ni-Sepharose. Med15 polypeptides were further 
purified using HiTrap Heparin (GE Healthcare) in 20 mM HEPES (pH 7), 1 mM DTT, 0.5 
mM PMSF eluting with either a 50–350 mM NaCl gradient (ABD1 and ABD2) or a 200–
600 mM NaCl gradient (ABD3, ABD123, and KIX123). Gcn4 AD derivatives 1–134 and 
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101–134 were further purified by chromatography on Source 15Q (GE Healthcare) using a 
50–350 mM NaCl gradient. Gcn4 1–100 and other nAD derivatives were purified using 
Source 15Q and HiTrap Phenyl FF (GE Healthcare). Protein was loaded to Source 15Q at 
120 mM NaCl and flowed through the column. This unbound fraction was adjusted to 0.8 M 
(NH4)2SO4, bound to phenyl FF, and eluted with an 800–0 mM (NH4)2SO4 gradient. All 
proteins were further purified using size exclusion chromatography on Superdex 75 10/30 
(GE Healthcare). Proteins used in fluorescence polarization and isothermal titration 
calorimetry were eluted in 20 mM KH2PO4 (pH 7.5), 200 mM KCl. Proteins used in cross-
linking-MS were eluted in PBS (pH 7.2). Proteins used in NMR were eluted in 20 mM 
NaH2PO4 (pH 6.5), 200 mM NaCl, 0.1 mM EDTA, 0.1 mM PMSF, 5 mM DTT. The 
concentration of the purified proteins was determined by UV-Vis (ultraviolet-visible) 
spectroscopy with extinction coefficients calculated with ProtParam (Gasteiger et al., 2005).
FP and ITC Binding Experiments
Gcn4 peptides used in fluorescence polarization were labeled with Oregon Green 488 dye 
(Invitrogen) as previously described (Herbig et al., 2010). FP measurements were conducted 
using a Beacon 2000 instrument as previously described (Herbig et al., 2010). Protein 
concentrations for titrations with Gcn4 nAD and Gcn4 cAD were as described (Herbig et al., 
2010), except for Gcn4 cAD versus Med15 ABD3 (0–225 μM). Titrations between Gcn4 
tAD and Med15 were performed with 15 concentrations of Med15 spanning 0–135 μM 
(KIX) or 0–250 μM (ABD1, ABD2, ABD3, ABD123, and KIX123). FP data were analyzed 
using Prism 7 (Graphpad Software) to perform non-linear regression analysis using the one-
site total binding model Y = Bmax*X/(Kd + X) + NS*X + Background, where Y equals 
arbitrary polarization units and X equals Med15 concentration.
Isothermal calorimetry titrations were performed using a Microcal ITC200 Microcalorimeter 
in 20 mM KH2PO4 (pH 7.5), 200 mM KCl as described in (Brzovic et al., 2011). The 
following protein concentrations were used, with the cell molecule listed first and the 
syringe molecule listed second: Med15 ABD1 (0.150 mM) versus Gcn4 nAD (1.50 mM); 
Gcn4 nAD (0.111 mM) versus Med15 ABD2 (1.60 mM); Gcn4 nAD (0.111 mM) versus 
Med15 ABD3 (1.12 mM); Med15 ABD1 (0.270 mM) versus Gcn4 cAD (2.37 mM); Med15 
ABD2 (0.224 mM) versus Gcn4 cAD (2.35 mM); and Med15 ABD3 (0.236 mM) versus 
Gcn4 cAD (2.35 mM). Calorimetric data were plotted and fit with a single binding site 
model using Origin 7.0 software (Microcal). Some affinities could not be measured by ITC, 
either due to weak binding or low heats of binding.
Protein Crosslinking and Sample Preparation for Mass Spectrometry
50 μg of Med15 158–651 Δ239–272, Δ373–483 (ABD123) or Med15 1–651 Δ239–272, 
Δ373–483 (KIX123) was mixed with 3x molar excess of Gcn4 1–140. Samples were 
incubated with 5 mM (for ABD123 experiments) or 7.5 mM (for KIX123 experiments) EDC 
(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; Thermo Scientific), and 2 
mM Sulfo-NHS (Thermo Scientific) in 100 μL total volume for 2 hr at room temperature. 
Protein samples were reduced with 50 mM TCEP and denatured with 8 M urea at 37°C for 
15 min. The samples were then alkylated in the dark at 37°C with 15 mM iodoacetamide for 
1 hr. The samples were then diluted 10-fold with 100 mM ammonium bicarbonate and 
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digested with trypsin (1:15 w/w) overnight at 37°C. Digested samples were purified by C18 
chromatography (Waters), eluted in 80% acetonitrile 0.15 trifluoroacetic acid, and dried in a 
SpeedVac.
Mass Spectrometry for Identification of Crosslinks
Peptides were analyzed using a Thermo Scientific Orbitrap Elite with HCD fragmentation 
and serial MS events that included one FTMS1 event at 15,000 resolution followed by 10 
FTMS2 events at 7,500 resolution. Other instrument settings included the following: charge 
state rejection: +1, +2, +3, and unassigned charges; monoisotopic precursor selection 
enabled; dynamic exclusion enabled: repeat count 1, exclusion list size 500, exclusion 
duration 30 s; HCD normalized collision energy 35%, isolation width 3 Da, minimum signal 
count 5,000; MS mass range: >1,500, use m/z values as masses enabled; and FTMS MSn 
AGC target 500,000, FTMS MSn Max ion time 300 ms. Peptides were resolved by online 
reverse phase HPLC (high-performance liquid chromatography) using a 90 min gradient 
from 5% ACN to 40% ACN.
To identify EDC-crosslinked peptides, two different database search algorithms were used: 
pLink (Yang et al., 2012) and in-house-designed Nexus (Luo et al., 2015). pLink was run 
with default settings (precursor monoisotopic mass tolerance: ±10 ppm; fragment mass 
tolerance: ±20 ppm; up to 4 isotopic peaks; max evalue 0.1; static modification on cysteines; 
57.0215 Da; differential oxidation modification on methionines; 15.9949 Da) using a 
database containing the target protein sequences. For Nexus searches, a protein database 
containing the forward and reversed sequences of the target proteins was used with the 
following parameter settings: up to three miscleavages; static modification on cysteines 
(+57.0215 Da); differential oxidation modification on methionines (+15.9949 Da); and 
differential modification on the peptide N-terminal glutamic acid residues (−18.0106 Da) or 
N-terminal glutamine residues (−17.0265 Da). GluC and trypsin were specified as the 
digestion enzymes, and a 5% FDR (false discovery rate) was used for both searches. After 
performing the pLink and the Nexus analyses, the search results were combined, and each 
spectrum was manually evaluated for the quality of the match to each peptide using the 
COMET/Lorikeet Spectrum Viewer (TPP). A crosslinked peptide was considered to be 
confidently identified if at least four consecutive b or y ions for each peptide was observed 
and the majority of the observed ions were accounted for.
NMR Experiments and Resonance Assignments
NMR HSQC titration, dynamics, and spin-label experiments were completed on a Bruker 
500 MHz AVANCE spectrometer. All spectra were collected at 25°C in NMR buffer (20 
mM sodium phosphate, 150 mM NaCl, 0.1 mM EDTA, 0.1 mM PMSF, and 5 mM DTT) 
with 7% D2O, unless otherwise specified. Spin-label samples were in NMR buffer but with 
no DTT; dynamics and titration samples were in NMR buffer but with 200 mM NaCl 
because ABD3 is more stable at higher salt.
(1H,15N)- and (1H,13C)-HSQC titration experiments were completed for all Gcn4-
AD:Med15-ABD combinations by adding unlabeled AD (nAD, cAD, tAD) or ABD (ABD1, 
ABD2, ABD3, ABD123) to a ~200 μM [13C,15N]-AD or ABD sample, maintaining a 
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constant concentration of the labeled species. T1 and T2 15N-Trosy HSQC experiments for 
200 μM [13C,15N]-nAD and 200 μM [13C,15N]-nAD + 600 μM ABD1 were collected in an 
interleaved manner with 8 points each (Zhu et al., 2000). T1 delays were 10, 40, 80, 120, 
160, 320, 640, and 1,000 ms; T2 cpmg loop delays were 8.48, 16.96, 25.44, 33.92, 42.40, 
50.88, 59.36, and 67.84 ms. T1 and T2 for each residue were fitted to a single exponential 
with errors reflecting the quality in the fit.
Paramagnetic relaxation enhancement (PRE) experiments were performed as for 
cAD:ABD1 (Brzovic et al., 2011) but at lower saturation. The spin-label 4-(2-
iodoacetamido)-TEMPO was incorporated at T82C (nAD and tAD), T105C (tAD), and 
S117C (cAD and tAD) by incubating the AD Cys mutants with 10x TEMPO overnight at 
room temperature, followed by several hours at 30°C. Excess TEMPO was removed by 
elution over a Nap-10 column and buffer exchange during concentration. 15N- and 13C-
HSQC spectra of [13C,15N]-ABD1 and [13C,15N]-ABD2 with spin-labeled ADs at a ~2:1 
ABD:AD concentration ratio were collected in the presence (reference intensity, Idia) and 
absence of 3 mM ascorbic acid (Ipara). A control sample was collected of [13C,15N]-ABD2 
with 500 μM free TEMPO, with and without 3 mM ascorbic acid.
Gcn4 tAD (aa 1–134) chemical shift assignments were transferred from nAD (aa 1–100) and 
cAD (aa 101–134) assignments (Brzovic et al., 2011) where possible and verified by 
standard backbone triple-resonance experiments (HNCA, HNCOCA, HNCOCACB, 
HNCACB, and HNCO) obtained on a 400 μM [13C,15N]-tAD sample using Bruker 500 and 
600 MHz Avance spectrometers. Gcn4 nAD chemical shift assignments were transferred 
from mini-nAD (Gcn4 1–100, Δ21–40, 52–60) where possible and verified by standard 
backbone triple-resonance experiments obtained on a 350 μM [13C,15N]-nAD + 620 μM 
ABD1 sample using Bruker 500 and 600 MHz Avance spectrometers. Assignments of free 
nAD were determined by following HSQC titration trajectories of nAD + ABD1. Mini-nAD 
assignments were obtained on a 600 μM [13C,15N]-mini-nAD sample using standard 
experiments on a Varian INOVA 600 or 800 MHz instruments located at Pacific Northwest 
National Laboratories.
Med15 ABD2 (residues 277–368) backbone and side-chain chemical shift assignments were 
obtained on ~1 mM [13C,15N]-ABD2 using standard experiments (HNCA, HNCOCA, 
HNCACB, HNCO, 15N-TOCSY, 15N-NOESY, aromatic and aliphatic 13C-NOESY, 
HNHAHB, HCCONH, CCONH, HCCH-TOCSY, and HCCH-COSY) on Bruker 600 and 
800 MHz Avance spectrometers. 13C-NOESY and HCCH experiments were collected in 
D2O NMR buffer. HSQC and NOESY experiments were also collected on a [13C,15N]-
F319Y ABD2 mutant sample to assist in assignments of aromatic residues and NOEs 
(Figure S4A). (1H,15N)-HSQC-IPAP experiments for measuring DNH RDCs were collected 
on a 15N-ABD2 sample at 22°C using a C12E6/hexanol mixture for alignment (Higman et 
al., 2011) on a Bruker 800 MHz Avance spectrometer.
The NH chemical shift perturbation was calculated according to ΔδNH (ppm) = sqrt [ΔδH2 + 
(ΔδN/5)2]. Component 1H and 15N CSPs are (freeform—bound form) in ppm. Secondary 
structure propensity was determined from backbone chemical shifts using the Neighbor-
Corrected Structural Propensity Calculator (ncSPC) (Tamiola and Mulder, 2012). Max CSP 
Tuttle et al. Page 15
Cell Rep. Author manuscript; available in PMC 2018 April 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
as in Figure S3B represents the maximum CSP of any residue within each defined 
hydrophobic cluster.
NMR Solution Structure
The structure of freeform Med15 ABD2 (aa 277–368) was determined based on chemical 
shifts, NOEs, and N-H RDCs using the Xplor-NIH software (Schwieters et al., 2003) with 
the EEFx implicit water potential (Tian et al., 2014). NOEs were assigned manually and 
used as distance restraints. Dihedral backbone restraints were calculated from backbone 
chemical shifts using TALOS (Shen and Bax, 2013) and were only used for residues with 
“strong” database matches. Structure calculations were based on the recommended eefx/
fold.py and refine.py scripts, which are included with the software. Simulations start from an 
extended conformation of ABD2, followed by rounds of simulated annealing and cooling to 
find the 20 lowest energy of 200 generated structures. Structure validation and statistics 
(Table S3) were determined using the Protein Structure Validation Software (PSVS) web 
server (Basu et al., 2008) and Procheck via the wwPDB submission (Berman et al., 2003). 
Electrostatic surfaces were generated using PDB2QPR and the APBS tool in pymol 
(Dolinsky et al., 2004).
Quantification and Statistical Analyses
mRNA Quantification—Steady-state mRNA levels were quantitated by qRT-PCR as 
described above and in Herbig et al. (2010).
Mass Spectrometry and Data Analysis—EDC-crosslinked peptides were analyzed on 
a Thermo Scientific Orbitrap Elite at the Proteomics facility at the Fred Hutchinson Cancer 
Research Center, and data were analyzed as described (Knutson et al., 2014). Two different 
database search algorithms were used to identify EDC-crosslinked peptides: pLink (Yang et 
al., 2012) and the in-house-designed Nexus (Luo et al., 2015). A 5% FDR was used for the 
results from both searches. Spectra were manually evaluated using the COMET/Lorikeet 
Spectrum Viewer (Trans-Proteomic Pipeline) (Knutson et al., 2014).
NMR Analysis—All NMR spectra were processed using NMRPipe (Delaglio et al., 1995) 
and analyzed in nmrViewJ (Johnson, 2004). NMR peak intensities for spin-label 
experiments were quantified using NMRviewJ, and error bars reflect noise levels of the 
spectra. Peak centers for RDC measurements were determined using FuDA (Hansen et al., 
2007). Percent saturation was calculated based on the Kd for each A:B complex according to 
%sat = [AB]/A = (1/A)*(C/2 + (C2 – 4*A*B)0.5), where A = [Atotal], B = [Btotal], and C = A 
+ B + Kd.
DATA AND SOFTWARE AVAILABILITY
The solution structure of Med15 ABD2 has been deposited in the Protein Data Bank with 
the accession code PDB: 6ALY. NMR chemical shifts, NOEs, and RDCs have been 
deposited to the BioMagResBank with the accession numbers BioMagResBank: 30330 for 
ABD2 and BioMagResBank: 27207 for Gcn4 tAD 1–134. NMR and crosslinking data have 
been deposited in the Mendeley Data repository (https://doi.org/10.17632/twjfm5rnnm.1).
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Tandem ADs of Gcn4 interact with Med15 ABDs in a fuzzy “free-for-all” 
complex
• Weak AD-ABD interactions significantly contribute to transcription activation
• Solution structure of Med15 ABD2 is reported
• Med15 ABDs may be designed to accommodate fuzzy interactions
Tuttle et al. Page 21
Cell Rep. Author manuscript; available in PMC 2018 April 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Gcn4 tAD Crosslinks to Each Med15 ABD and KIX
(A) Gcn4 consists of the tAD and bZIP subdomains. The expanded view of the tAD 
highlights key hydrophobic residue clusters located in the nAD (blue) and cAD (red). The 
four structured Med15 domains in the activator-binding region and the Q-rich linkers 
between the domains are indicated. (B and C) ABD123-tAD (B) and KIX123-tAD (C) 
crosslinking results. Lines between the Med15 and Gcn4 constructs indicate the sites of 
crosslinking that were identified by mass spectrometry. Dashed boxes indicate deleted 
regions of the wild-type sequence for each Med15 construct. Red and blue bars within each 
subdomain indicate acidic and lysine residues, respectively.
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Figure 2. Gcn4 nAD and cAD Independently Interact with Med15 ABDs
(A–D) The NH chemical shift perturbation (CSP) of Gcn4 upon addition of Med15 ABD1 
(A), ADB2 (B), ABD3 (C), or ABD123 (D). For each ABD, nAD and cAD regions have 
similar CSPs as independent regions (left) or in the context of full-length tAD 1–134 (right). 
See Figure S2 for (1H,15N)-HSQC titration spectra.
(C) Many cAD region peaks are lost after ~50% saturation for both the cAD + ABD3 and 
tAD + ABD3 titrations.
(D) HSQC peaks for tAD residues 91–99 of the tAD + ABD123 titration are lost at 
saturation levels >50%, so CSPs for nAD + ABD123 are also shown at 50% saturation for 
comparison; dashed black lines show full saturation data for nAD+ABD123 in (D). In all 
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panels, ** indicates situations where not all peaks trajectories could be followed to complete 
saturation.
(E) Backbone dynamics of nAD free (blue) and bound to ABD1 (orange). Increase of R2 in 
nAD:ABD1 for each of the hydrophobic clusters suggests direct interaction of these regions 
with ABD1. Hydrophobic regions are highlighted by blue (nAD) and red (cAD) bars 
beneath each plot.
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Figure 3. Structure and Surface Properties of Med15 ABD2
(A) The 20 lowest energy structures colored blue to red from the N to C termini.
(B and C) Hydrophobic (B; magenta) and electrostatic (C; red, <−5.0 kT/e; blue, >5.0 kT/e) 
surfaces plotted for the front side and back side of ABD2. Disordered N and C termini are 
not shown for surface representations. Electrostatic surfaces were generated using 
PDB2QPR and the APBS tool in pymol (Dolinsky et al., 2004). Hydrophobic surfaces are 
colored from magenta (most hydrophobic) to white according to the Eisenberg 
hydrophobicity scale.
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Figure 4. Med15 ABDs Show Widespread and Similar CSPs with Each Gcn4 AD
(A and B) Expanded region of the (1H,15N)-HSQC titration spectra of ABD1 (A) and ABD2 
(B) with Gcn4 nAD, cAD, and tAD. Both ABD1 and ABD2 show very similar chemical 
shift trajectories whether nAD (left), cAD (middle), or tAD (right) is added. Values in 
parentheses are the percent saturation at the endpoint (purple spectrum).
(C and D) The CSPs of ABD1 + tAD (C) and ABD2 + tAD (D) plotted on the structures of 
ABD1 (2LPB) and ABD2 (6ALY), respectively. A redder surface color indicates a larger 
CSP.
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Figure 5. Paramagnetic Relaxation Enhancement Experiments of AD:ABD Complexes
(A) Spin label was attached at either side of the main clusters of nAD, cAD, and tAD 
(position indicated by a star).
(B) Each spin-labeled AD causes similar peak intensity loss at ABD2 (shown here for CH 
groups) and at ABD1 (see Figure S6 for NH and CH results). The results of a control 
experiment of ABD2 + free TEMPO are shown as light blue bars (see also Figure S6F).
(C and D) Surface plots for ABD1 + tAD T82C-TEMPO (C) and ABD2 + tAD T82C-
TEMPO (D). Residues are colored red if the amide PRE < 0.7 or CH group PRE < 0.6.
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Figure 6. Model of the Fuzzy Gcn4-Med15 Complex
Transient fuzzy interactions of nAD and cAD with Med15 ABD subunits allows for 
significant contributions from even the weakest interacting parts by reducing the probability 
of total dissociation of Gcn4 tAD from Med15. Gcn4 bZIP and DNA structure from PDB: 
1DGC are shown.
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